Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 12OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 9459Neoplasms 6577Prostatic Neoplasms 4394Colorectal Neoplasms 3964Lung Neoplasms 3633Carcinoma, Non-Small-Cell Lung 3576Pancreatic Neoplasms 2472Carcinoma, Hepatocellular 2407Leukemia, Myeloid, Acute 2261Multiple Myeloma 2115Stomach Neoplasms 2104Neoplasm Metastasis 1911Head and Neck Neoplasms 1864Ovarian Neoplasms 1770Precursor Cell Lymphoblastic Leukemia-Lymphoma 1732Lymphoma 1728Brain Neoplasms 1696Rectal Neoplasms 1672Melanoma 1652Colonic Neoplasms 1629Leukemia 1498Uterine Cervical Neoplasms 1493Recurrence 1480Esophageal Neoplasms 1309Glioblastoma 1303Lymphoma, Non-Hodgkin 1202Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1108Urinary Bladder Neoplasms 1077Lymphoma, Follicular 1067

Interventions

enzalutamide 2sapanisertib 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-Resistant Prostate Cancer × Clear all
NCT04419402 2024-02-07

ENZA-p

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown
162 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02125357 2020-08-07

Sequencing Abiraterone and Enzalutamide in mCRPC

British Columbia Cancer Agency

Phase 2 Completed
202 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02091531 2019-11-21

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
9 enrolled 10 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡